MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biomarkers

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma

Oncotarget 2017 March [Epub ahead of print] [Link] Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare tumor linked to a dismal prognosis. Even the most effective chemotherapeutical regime of pemetrexed combined with cisplatin leads to a […]

Comments Off on Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma

Epidemiology of Environmental Exposure and Malignant Mesothelioma.

Journal of Thoracic Oncology 2017 April [Epub ahead of print] [Link] Bian L, van Gerwen M, Bonassi S, Taioli E; IASLC Mesothelioma Taskforce Abstract While the association between exposure to asbestos and malignant mesothelioma (MM), particularly malignant pleural mesothelioma (MPM) has been well established, the health impact of environmental exposure (EE) to asbestos is less […]

Comments Off on Epidemiology of Environmental Exposure and Malignant Mesothelioma.

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.

Respiratory Research 2017 April [Link] Cortes-Dericks L, Schmid RA Abstract Malignant pleural mesothelioma (MPM) is a rare and highly drug resistant tumor arising from the mesothelial surfaces of the lung pleura. The standard method to confirm MPM is the tedious, time-consuming cytological examination of cancer biopsy. Biomarkers that are detectable in pleural effusion or patient […]

Comments Off on CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.

Analysis of fibulin-3 after exposure to asbestos-like fibers.

Environmental Research 2017 April [Epub ahead of print] [Link] Rapisarda V, Caltabiano R, Musumeci G, Castrogiovanni P, Ferrante M, Ledda C, Lombardo C, Graziano AC, Cardile V, Loreto C Abstract A significantly increased incidence of malignant mesothelioma in Biancavilla (Sicily, Italy) has been ascribed to exposure to fluoro-edenite, a fibrous amphibole extracted from a local […]

Comments Off on Analysis of fibulin-3 after exposure to asbestos-like fibers.

A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.

Journal of Thoracic Oncology 2017 April [Epub ahead of print] [Link] Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, Felley-Bosco E Abstract INTRODUCTION: BRCA1-associated protein-1, BAP1, is a tumor suppressor involved in multiple cellular processes such as transcriptional regulation, chromatin modification by deubiquitinating histone 2A and DNA repair. BAP1 mutations are […]

Comments Off on A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.

A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Cancer Genomics & Protemics 2017 March [Link] Creaney J, Dick IM, Leon JS, Robinson BW Abstract Abstract Backgound/Aim: Malignant mesothelioma (MM) is an aggressive and fatal pleural cancer. The cell secretome offers information allowing insight into the pathogenesis of MM while offering the possibility to identify potential therapeutic targets and biomarkers. In the present study […]

Comments Off on A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.

Comments Off on Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases

Disease Markers 2017 [Epub March 2017] [Link] Ying S, Jiang Z, He X, Yu M, Chen R, Chen J, Ru G, Chen Y, Chen W, Zhu L, Li T, Zhang Y1, Guo X, Yin X, Zhang X, Lou J Abstract High-mobility group box 1 (HMGB1) functions as a proinflammatory cytokine and is one of the […]

Comments Off on Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases

Targeting BAP1: a new paradigm for mesothelioma

Lung Cancer (Netherlands) 2017 March 18 [Epub ahead of print] [Link] Schunselaar LM, Zwart W, Baas P Abstract New treatment strategies for malignant pleural mesothelioma (MPM) are important. BAP1 mutations are present in 47-67% of the MPM tumors, making this a good target for treatment. Multiple functions of BAP1 are investigated in the preclinical situation. […]

Comments Off on Targeting BAP1: a new paradigm for mesothelioma

Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.

Occupational and Environmental Medicine 2017 March 25 [Epub ahead of print] [Link] De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell’Anno I, Pellè L, Vodicka P, Mutti L, Foddis R, Cristaudo A, Gemignani F, Landi S Abstract BACKGROUND: Soluble mesothelin-related […]

Comments Off on Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.